Amancio Carnero Moya

Title: Amancio Carnero Moya: Innovator in Lung Cancer Treatment

Introduction

Amancio Carnero Moya is a notable inventor based in Seville, Spain. He has made significant contributions to the field of cancer treatment, particularly in predicting patient responses to therapies. His work focuses on improving therapeutic decision-making for lung cancer patients.

Latest Patents

Amancio Carnero Moya holds a patent for a method involving N-cadherin and FGFR1 and/or FGFR4. This invention is aimed at predicting the response of patients suffering from lung cancer to treatment with FGFR inhibitors. The method allows clinicians to classify subjects as responsive or unresponsive to treatment, facilitating better therapeutic decisions. The patent also details how to analyze and interpret the biomarkers N-cadherin, FGFR1, and FGFR4, ensuring that FGFR inhibitors are administered only to those who will benefit from them.

Career Highlights

Throughout his career, Amancio has worked with esteemed organizations such as Fundación de Investigación Hospital 12 de Octubre and Servicio Andaluz de Salud. His experience in these institutions has contributed to his expertise in cancer research and treatment methodologies.

Collaborations

Amancio has collaborated with notable professionals in the field, including Luis Paz-Ares Rodríguez and Álvaro Quintanal Villalonga. These collaborations have further enriched his research and innovations in cancer treatment.

Conclusion

Amancio Carnero Moya's contributions to lung cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work exemplifies the importance of research and innovation in the medical field.